
    
      The DESSOLVE I clinical trial is to assess the safety and performance of the
      sirolimus-eluting MiStent for the treatment for improving coronary luminal diameter in
      patients with symptomatic ischemic heart disease due to discrete de novo lesions < 20 mm in
      length in the native coronary arteries with reference vessel diameters between 2.5 mm and 3.5
      mm.
    
  